It is well known that adverse effects which are observed in the early period of the usage of a drug get widely publicized, but as more experience in its use is gained, these adverse effects are understood to be not as frequent or as dangerous as initially thought. The early reports of cholestatic jaundice with chlorpromazine and the unconfirmed fear about fluoxetine increasing suicidal ideation are examples of this. It is also true that as experience with a pharmacological agent accumulates, the clinician and researcher become more aware of the true prevalence and significance of certain adverse effects which were initially unknown, or considered insignificant. The awareness about the teratogenicity of lithium and the occurrence of tardive dyskinesia and neuroleptic malignant syndrome with most anti-psychotics, are examples of this type of problem. Thus, as we survey the history of most pharmacological agents and for that matter, most treatment methods not only in psychiatry but in medicine in general, we find that our attitude towards a therapeutic modality goes through different phases.
The first is a phase of excitement where exaggerated claims are made about the efficacy and safety of the method, resulting in the widespread use of the method (often enhanced by the consumers demand for it based on sensational reports in the lay press), in many conditions whether indicated or not. This is followed by a phase of disillusionment when the treatment method is found to be incapable of doing all what was expected of it and reports about its undesirable effects gradually accumulate, resulting in its total rejection and non-availability even to those who could have been benefitted by it. The third phase is a period of reassessment and revaluation of the true benefits and disadvantages of the treatment modality based more on hard data and less on emotion and expectation. This leads to the final phase of acceptance, (albeit qualified), when a balance between unfounded optimism and unqualified rejection is struck. It is the responsibility of the clinician / researcher to hasten the process of any method of treatment reaching this final phase, through documentation of his observations. We are also endowed with the responsibility of enabling our patients and their families to make the right choices regarding treatment by presenting adequate information to them about available methods of treatment and also of taking steps to prevent further harm when the negative effect of a treatment method comes to our notice.
The lay public as well as uninformed professionals tend to believe that the occurrence of adverse or negative effects is a problem which occurs only in the case of pharmacological agents or physical methods of treatment like electroconvulsive therapy. The fact that psychosocial methods of treatment also can adversely affect a patient and / or his family is often ignored. Hadley and Strupp (1976) reported that psychotherapists themselves admitted that 3% to 6% of their patients became worse with therapy. Buckley et al (1987) found that 21% of psychotherapists who completed personal psychotherapy or psychoanalysis, ielt that the therapy had certain harmful effects on some aspects of their lives. The negative effects of psychotherapy on the clients personal, social or family life are found to correlate with specific characteristics of the patient, the therapist and the technique employed. Recent workers in this area have our attention to the potential for financial exploitation (Book. 1991) sexual exploitation (Appelbaum &Jogcrson. l°9l), emotional exploitation (Rosenbloom, 1992) and the possibility of the psychotherapeutic relationship being used as an instrument of coercion in political or religious matters (Alderdice and Alderdice, 1993) .
A new dimension to the possible adverse effects of psychotherapy was added by Kingdom et al (1986) who reported that a patient of theirs who underwent cognitive therapy for unipolar depression K.KURUV1LLA switched to hypomania. Since supportive psychotherapy, wherein suggestions and advice are given to the patient, is perhaps the most widely practiced psychotherapeutic technique in India, I believe, we have to be particularly conscious about the possibility of the negative effects of treatment. We should be humble enough to accept the fact that the possession of an M.D. or Ph.D. does not automatically confer on us the wisdom to provide the answers to all life's problems or the right to impose our views on the client; neither does it justify our propensity to dispense advice liberally using the excuse that the "Guru Chela" style of psychotherapeutic relationship has been advocated as the most appropriate one for our culture.
Some of the articles in this issue of the journal invite our attention to this special responsibility of the psychiatrist to his patient. Dr. Agarwal's presidential address on "Ethics in Psychiatry" draws our attention to the ethical issues involved in the different aspects of psychiatric practice, including the ethical standards to be followed in the choice of various treatment methods. He rightly emphasizes, "treatment decisions should include not only the symptomatic recovery, but also increase the patient's ability for relating socially for gainful employment and ultimately personal happiness".
While the usefulness of antipsychotics in the treatment of various psychotic disorders is unquestionable, the emergence of tardive dyskinesia has become a major problem especially because the effectiveness of currently available methods for its treatment is limited. Datta et al report that 25.5% of their patients who were treated with antipsychotics for three months or more developed tardive dyskinesia and that age, total antipsychotic dosage and duration of antipsychotic exposure positively correlated with the occurrence of persistent tardive dyskinesia.
These findings should once again remind us of the axiom that the use of antipsychotics should be limited to the smallest possible effective dosage for the shortest possible time. The high prevalence of tardive dyskinesia reported in research studies in contradistinction to his observation in regular follow-up clinics, just goes to prove the point that 'what the mind does not know the eye does not see'. Every clinician should therefore be alert to the risk of his patient developing tardive dyskinesia while on antipsychotics, because early detection and reduction of the medication are helpful in reversing it in about 8% of the victims.
The newer antidepressants, especially fluoxetine, have been hailed as miracle drugs and advocated for everything ranging from post traumatic stress disorder to premature ejaculation. Though fluoxetine is free from the anticholinergic effects which make tricyclic antidepressants unacceptable to many patients, it is well documented that its use can be associated with side effects like nausea, headache, nervousness, insomnia, anxiety, akathisia and seizures (Cooper, 1988) . In this issue, Andrade reports a case where treatment of depression with fluoxetine resulted in vascular headache which necessitated concurrent use of propranolol. As with the use of tricyclic antidepressants and monoamine oxidase inhibitors, manic switch is reported with fluoxetine also. Damodaran et al describe a patient with leukoencephalopathy who when treated with fluoxetine for depressive symptoms, switched to mania.
The report by Srinivasan et al about a patient who developed manic symptoms following hypnotherapy for depression is a valuable addition toour understanding that the potential for adverse effects is not only inherent in physical methods of treatment but also in psychological methods.
The implications of the short and long term adverse effects of psychiatric treatment methods are important not just to the psychiatrist, but also to everyone involved in the care of the mentally ill. As we develop newer strategies to reach the unreached, like training medical officers, health assistants and multipurpose workers in the detection and management of mental illness in the community (as Naik et al and Nagarajiah et al report in this issue), we should also be aware of the limitations of such programs, such as the relatively limited attention being paid to the detection and management of adverse effects. It is hoped that as these training programs get well established and refined, strategies to deal with these problems also will be further developed.
Our responsibility, as therapists using powerful pharmacological and psychological methods of treatment, which can lead to both beneficial and harmful effects on our patients, can be summarized in the words of Sidney Crown (1983) -"Every treatment from aspirin to steroids and psychotropics to psychotoxics, if it is effective inevitably has both curative and unwanted side effects. The latter must relate to the patient selected for treatment, to the condition treated and to the competence or otherwise of the person administering the treatment. Unwanted effects should be recognized, their sources spelled EDITORIAL out and strategies suggested as to how they might be overcome".
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